NZ248727A - Nanoparticles with x-ray contrast agent with high molecular weight surfactant adsorbed on the surface - Google Patents

Nanoparticles with x-ray contrast agent with high molecular weight surfactant adsorbed on the surface

Info

Publication number
NZ248727A
NZ248727A NZ248727A NZ24872793A NZ248727A NZ 248727 A NZ248727 A NZ 248727A NZ 248727 A NZ248727 A NZ 248727A NZ 24872793 A NZ24872793 A NZ 24872793A NZ 248727 A NZ248727 A NZ 248727A
Authority
NZ
New Zealand
Prior art keywords
composition
modifier
cloud point
surfactant
molecular weight
Prior art date
Application number
NZ248727A
Other languages
English (en)
Inventor
George C Na
Original Assignee
Eastman Kodak Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastman Kodak Co filed Critical Eastman Kodak Co
Publication of NZ248727A publication Critical patent/NZ248727A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0476—Particles, beads, capsules, spheres
    • A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/049—Surface-modified nanoparticles, e.g. immune-nanoparticles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ248727A 1992-12-17 1993-09-21 Nanoparticles with x-ray contrast agent with high molecular weight surfactant adsorbed on the surface NZ248727A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/991,909 US5326552A (en) 1992-12-17 1992-12-17 Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants

Publications (1)

Publication Number Publication Date
NZ248727A true NZ248727A (en) 1995-04-27

Family

ID=25537712

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ248727A NZ248727A (en) 1992-12-17 1993-09-21 Nanoparticles with x-ray contrast agent with high molecular weight surfactant adsorbed on the surface

Country Status (17)

Country Link
US (2) US5326552A (enExample)
EP (1) EP0602700A3 (enExample)
JP (1) JPH06192131A (enExample)
KR (1) KR940013544A (enExample)
AU (1) AU664115B2 (enExample)
CA (1) CA2107165A1 (enExample)
CZ (1) CZ266893A3 (enExample)
FI (1) FI935396L (enExample)
HU (1) HUT67265A (enExample)
IL (1) IL107875A0 (enExample)
MX (1) MX9306012A (enExample)
MY (1) MY109875A (enExample)
NO (1) NO934425L (enExample)
NZ (1) NZ248727A (enExample)
PH (1) PH30158A (enExample)
SK (1) SK142793A3 (enExample)
TW (1) TW240171B (enExample)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5525327A (en) * 1994-04-14 1996-06-11 Sterling Winthrop Inc. Polymeric x-ray contrast compositions containing iodinated polymeric beads and microcrystaline cellulose
US5368837A (en) * 1994-04-14 1994-11-29 Sterling Winthrop Inc. X-ray contrast compositions containing an organic crystalline X-ray contrast agent and a cellulose derivative
US6645463B1 (en) 1994-05-16 2003-11-11 The Board Of Regents Of The University Of Michigan Blood-pool selective carrier for lipophilic imaging agents
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
ATE274341T1 (de) * 1995-02-24 2004-09-15 Elan Pharma Int Ltd Nanopartikel-dispersionen enthaltende aerosole
US5962380A (en) * 1995-06-06 1999-10-05 Chevron Chemical Company Llc Fluorocarbon elastomer compatibility improving agent having wear inhibition effect
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
AU743917B2 (en) * 1996-08-22 2002-02-07 Rtp Pharma Corporation Compositions comprising microparticles of water-insoluble substances
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
RU2186562C2 (ru) * 1996-08-22 2002-08-10 Ресеч Трайангл Фармасьютикалс Лтд. Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
GB9705340D0 (en) * 1997-03-14 1997-04-30 Nycomed Imaging As Compositions
WO1998048847A1 (en) * 1997-04-25 1998-11-05 Nycomed Imaging As Nanoparticle composition containing iodinated x-ray contrast agent as stabilizer for thermal sterilization
GB9712981D0 (en) * 1997-06-19 1997-08-27 Nycomed Imaging As Compositions
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
ATE318132T1 (de) 1998-03-30 2006-03-15 Jagotec Ag Zubereitungen enthaltend mikropartikel von wasserunlöslichen substanzen, sowie verfahren zu deren herstellung
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
DK1079808T3 (da) 1998-05-29 2004-06-07 Skyepharma Canada Inc Præparater med termisk beskyttede mikropartikler og fremgangsmåde til slutdampsterilisering deraf
DE69912441T2 (de) 1998-08-19 2004-08-19 Skyepharma Canada Inc., Verdun Injizierbare wässerige propofoldispersionen
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
EP2266542A3 (en) * 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
MXPA01004381A (es) * 1998-11-02 2005-09-08 Elan Corp Plc Composicion de multiparticulado de liberacion modificada.
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
AU767154B2 (en) 1998-11-20 2003-10-30 Skyepharma Canada Inc. Dispersible phospholipid stabilized microparticles
US6309596B1 (en) * 1998-12-15 2001-10-30 Bausch & Lomb Incorporated Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by a poloxamine
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
EP1214059B1 (en) * 1999-09-21 2005-05-25 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
WO2002094215A2 (en) * 2000-11-20 2002-11-28 Elan Pharma International Ltd. Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6897196B1 (en) * 2001-02-07 2005-05-24 The Regents Of The University Of California pH sensitive lipids based on ortho ester linkers, composition and method
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
EP1401401B1 (en) * 2001-06-22 2005-03-30 Marie Lindner Method for high through put screening using a small scale mill or microfluidics
US7687053B2 (en) * 2001-08-20 2010-03-30 Boston Scientific Scimed, Inc. Embolic compositions with non-cyanoacrylate rheology modifying agents
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
EP1429731B1 (en) * 2001-09-19 2007-01-03 Elan Pharma International Limited Nanoparticulate insulin formulations
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CA2463495C (en) * 2001-10-12 2011-05-24 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030152519A1 (en) * 2001-11-07 2003-08-14 Reinhard Koenig Methods for vascular imaging using nanoparticulate contrast agents
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
JP4598399B2 (ja) * 2002-02-04 2010-12-15 エラン ファーマ インターナショナル，リミティド 表面安定剤としてリゾチームを有するナノ粒子組成物
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
AU2003222027A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
AU2003224808A1 (en) * 2002-03-28 2003-10-13 Imcor Pharmaceutical Company Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
PT1494649E (pt) 2002-04-12 2012-04-11 Alkermes Pharma Ireland Ltd Formulações de megestrol em nanopartículas
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
JP2005529911A (ja) * 2002-05-06 2005-10-06 エラン ファーマ インターナショナル，リミティド ナノ粒子ナイスタチン製剤
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP1511467A1 (en) * 2002-06-10 2005-03-09 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
JP4776229B2 (ja) 2002-07-16 2011-09-21 エラン ファーマ インターナショナル，リミティド 安定なナノ粒子活性物質の液体投与組成物
US20050255164A1 (en) * 2002-08-15 2005-11-17 Yunging Liu Solid nano pharmaceutical formulation and preparation method thereof
JP4878839B2 (ja) 2002-09-11 2012-02-15 エラン ファーマ インターナショナル，リミティド ゲル安定化ナノパーティクル活性物質組成物
AU2003268380A1 (en) * 2002-10-04 2004-05-04 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
JP4776233B2 (ja) * 2002-11-12 2011-09-21 エラン ファーマ インターナショナル，リミティド 摩損しにくくかつプルランを含む速崩壊性固形製剤
EP1593091B1 (en) 2003-01-25 2013-07-17 Seno Medical Instruments, Inc. High contrast optoacoustical imaging using non-spherical nanoparticles
WO2004078162A1 (en) * 2003-01-31 2004-09-16 Elan Pharma International Ltd. Nanoparticulate topiramate formulations
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
JP2007501683A (ja) * 2003-05-22 2007-02-01 エラン ファーマ インターナショナル リミテッド γ線照射によるナノ粒子活性物質分散体の滅菌法
JP2007501839A (ja) * 2003-08-08 2007-02-01 エラン ファーマ インターナショナル リミテッド 新規メタキサロン組成物
JP2005170923A (ja) * 2003-10-21 2005-06-30 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤およびその製造方法
ES2366646T3 (es) * 2003-11-05 2011-10-24 Elan Pharma International Limited Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial.
WO2006009022A1 (ja) * 2004-07-21 2006-01-26 Konica Minolta Medical & Graphic, Inc. リポソーム含有ｘ線造影剤およびその製造方法
EP1776948B1 (en) * 2004-08-11 2015-12-09 Konica Minolta Medical & Graphic, Inc. Method of producing liposome-containing preparation
US20090155331A1 (en) * 2005-11-16 2009-06-18 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
KR101290115B1 (ko) * 2004-11-16 2013-07-29 엘커메스 파마 아일랜드 리미티드 주사가능한 나노입자형 올란자핀 제형
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
EP1835889A1 (en) * 2004-12-15 2007-09-26 Elan Pharma International Limited Nanoparticulate tacrolimus formulations
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
BRPI0606434A2 (pt) * 2005-01-06 2009-06-30 Elan Pharma Int Ltd formulações de candesartana nanoparticulada
AU2006214443C1 (en) 2005-02-15 2011-11-24 Alkermes Pharma Ireland Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
WO2006096462A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
KR20070118258A (ko) * 2005-03-16 2007-12-14 엘란 파마 인터내셔널 리미티드 나노입자형 류코트리엔 수용체안타고니스트/코르티코스테로이드 제제
CN101198316A (zh) * 2005-03-17 2008-06-11 伊兰制药国际有限公司 纳米微粒双膦酸盐组合物
EA200702049A1 (ru) * 2005-03-23 2008-02-28 Элан Фарма Интернэшнл Лтд. Композиции наночастиц кортикостероидов с антигистаминами
KR20080007580A (ko) * 2005-04-12 2008-01-22 엘란 파마 인터내셔널 리미티드 사이클로스포린을 함유하는 나노입자형 조절 방출 조성물
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
KR20080002939A (ko) * 2005-04-12 2008-01-04 엘란 파마 인터내셔널 리미티드 나노입자형 퀴나졸린 유도체 제제
EA200702444A1 (ru) * 2005-05-10 2008-04-28 Элан Фарма Интернэшнл Лимитед Композиции с наночастицами клопидогреля
WO2006132752A1 (en) * 2005-05-10 2006-12-14 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising vitamin k2
CN101287453A (zh) * 2005-05-16 2008-10-15 依兰药物国际有限公司 包含头孢菌素的毫微粒和控制释放组合物
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
US20060292214A1 (en) * 2005-06-03 2006-12-28 Elan Pharma International Limited Nanoparticulate acetaminophen formulations
EP1895984B8 (en) * 2005-06-03 2010-05-12 Elan Pharma International Limited Nanoparticulate imatinib mesylate formulations
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
JP2009517485A (ja) 2005-06-08 2009-04-30 エラン・ファルマ・インターナショナル・リミテッド セフジトレンを含むナノ粒子状および制御放出組成物
ATE446742T1 (de) * 2005-06-09 2009-11-15 Elan Pharma Int Ltd Nanopartikuläre ebastinformulierungen
EA200800041A1 (ru) * 2005-06-13 2008-04-28 Элан Фарма Интернэшнл Лтд. Составы с наночастицами клопидогреля, содержащие комбинацию клопидогреля и аспирина
US20100221327A1 (en) * 2005-06-15 2010-09-02 Elan Pharma International Limited Nanoparticulate azelnidipine formulations
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
CA2622758A1 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
BRPI0712130A2 (pt) * 2006-05-30 2012-01-17 Elan Pharma Int Ltd formulações de posaconazol em nanopartìculas
CA2657379A1 (en) * 2006-07-10 2008-01-17 Elan Pharma International Ltd. Nanoparticulate sorafenib formulations
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
AU2008278605A1 (en) * 2007-07-26 2009-01-29 Nanoscan Imaging, Llc Methods for imaging using improved nanoparticulate contrast agents
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
EP2268265A2 (en) * 2008-03-21 2011-01-05 Elan Pharma International Limited Compositions for site-specific delivery of imatinib and methods of use
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
HUE032426T2 (en) 2009-05-27 2017-09-28 Alkermes Pharma Ireland Ltd Inhibition of flake aggregation in nanoparticulate meloxicam formulations
US8901050B2 (en) 2010-03-31 2014-12-02 Chevron Oronite Company Llc Method for improving copper corrosion performance
US8933001B2 (en) 2010-03-31 2015-01-13 Chevron Oronite Company Llc Method for improving fluorocarbon elastomer seal compatibility
US9150811B2 (en) 2010-03-31 2015-10-06 Cherron Oronite Company LLC Method for improving copper corrosion performance
US8993496B2 (en) 2010-03-31 2015-03-31 Chevron Oronite Company Llc Method for improving fluorocarbon elastomer seal compatibility
US8716202B2 (en) 2010-12-14 2014-05-06 Chevron Oronite Company Llc Method for improving fluorocarbon elastomer seal compatibility
EP2873670A1 (en) 2013-11-14 2015-05-20 Bayer Pharma Aktiengesellschaft Bis azainositol zirconium complexes for X-ray imaging
EP3288957A4 (en) 2015-05-01 2019-01-23 Cocrystal Pharma, Inc. NUCLEOSIDE ANALOGUE FOR THE TREATMENT OF VIRUSES OF THE FLAVIVIIDAE FAMILY AND CANCER
CN114026067A (zh) 2019-06-05 2022-02-08 埃默里大学 用于治疗冠状病毒和小核糖核酸病毒感染的肽模拟物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3997470A (en) * 1971-10-20 1976-12-14 Mallinckrodt, Inc. Surfactant containing reagent formulations for assaying biological specimens and methods of preparing same
US4406878A (en) * 1978-08-02 1983-09-27 Eastman Kodak Company Iodinated contrast agent for radiography
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
DE4015741A1 (de) * 1990-05-16 1991-11-21 Metallgesellschaft Ag Verfahren zur herstellung von mg(pfeil abwaerts)2(pfeil abwaerts)si enthaltenden legierungen
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization

Also Published As

Publication number Publication date
AU4867293A (en) 1994-06-30
MX9306012A (es) 1995-01-31
KR940013544A (ko) 1994-07-15
HU9303490D0 (en) 1994-04-28
PH30158A (en) 1997-01-21
NO934425L (no) 1994-06-20
CZ266893A3 (en) 1994-08-17
FI935396A7 (fi) 1994-06-18
TW240171B (enExample) 1995-02-11
EP0602700A3 (en) 1994-12-21
IL107875A0 (en) 1994-04-12
HUT67265A (en) 1995-03-28
EP0602700A2 (en) 1994-06-22
NO934425D0 (no) 1993-12-06
FI935396L (fi) 1994-06-18
SK142793A3 (en) 1994-07-06
MY109875A (en) 1997-09-30
FI935396A0 (fi) 1993-12-02
US5447710A (en) 1995-09-05
JPH06192131A (ja) 1994-07-12
US5326552A (en) 1994-07-05
CA2107165A1 (en) 1994-06-18
AU664115B2 (en) 1995-11-02

Similar Documents

Publication Publication Date Title
US5447710A (en) Method of making nanoparticulate X-ray blood pool contrast agents using high molecular weight nonionic surfactants
EP0498482B1 (en) X-ray contrast compositions useful in medical imaging
AU665669B2 (en) Use of tyloxapol as a nanoparticle stabilizer and dispersant
JP3710811B2 (ja) 微小結晶製剤用の安定剤被膜としてのブチレンオキサイド−エチレンオキサイドブロック共重合体界面活性剤
EP0810855B1 (en) Polyalkylene block copolymers as surface modifiers for nanoparticles
AU662453B2 (en) Use of charged phospholipids to reduce nanoparticle aggregation
WO1996025182A1 (en) Process of preparing x-ray contrast compositions containing nanoparticles
WO1997004756A2 (en) Methacrylate backbone surfactants in nanoparticulate formulations